Guernsey woman feels at risk after nurse alarm failure
HSC is looking for a supplier to undertake its Nurse Call System Replacement Programme covering about 200 beds.It said the list of sites was "not exhaustive" and "may change once the process progresses"."The current nurse call systems from various providers, vary in age, with the majority 10 to 15 years old."Existing systems are maintained to ensure they continue working, and are not a clinical risk," it said.Joan, who knows what it is like to have a system fail, said: "It's very frightening."You're very vulnerable... this is supposed to keep you safe and it isn't if it isn't working."She said her system had been fixed but she was "worried all the time" it would fail again."You wonder if you're actually worth anything, because you're paying for it and you're not getting the service," she said.
David Inglis, chairman of Age Concern Guernsey, said the systems were a "lifeline" for many."There are 1,200 people out there [using a system]," he said, adding it was "really bad" if just one had suffered due to a system not functioning properly.He was also concerned how any system would work with the introduction of full fibre broadband to the island's communications network, replacing the current mixed fibre and copper wire operations.Those behind the full fibre roll-out said the system would mean connections would be faster, more stable and more reliable.Steve Ozanne, head of fixed networks at Sure, the telecoms company in charge of the technical side, said the utility wanted "to make sure it continues to work reliably on the new fibre network"."If you or someone you care for uses a lifeline health alarm, you're eligible for a free battery backup unit when switching to fibre," Mr Ozanne said.The company had also introduced a new lifeline device that used the mobile network, which it said would "continue to work if there is a power cut".
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
23 minutes ago
- The Independent
What is RSV? The main cause of hospital admissions for children
Health experts say the UK should brace for a surge in a potentially serious virus following a record number of cases in Australia. NHS officials said that the Australian winter is often a good predictor of how viruses will spread in England. In Australia, respiratory syncytial virus (RSV) cases have surged in recent months, and officials have said that cases have been steadily increasing in England since the start of 2025. NHS England has urged pregnant women to get the vaccine, which protects against RSV, in order to protect their newborn babies. The virus is a leading cause of death among babies and the main cause of hospital admissions for children. Kate Brintworth, chief midwifery officer for NHS England, said that while for most adults, RSV 'only causes mild, cold-like symptoms, for older adults and young children, it can lead to serious breathing problems that can end up in hospitalisation'. 'Getting vaccinated while pregnant is the best way to protect your baby from the moment they are born, and now is the time for mums to act, to make sure their babies are protected ahead of their first few months this winter, when there tends to be more bugs circulating.' Pregnant women can get the jab from 28 weeks of pregnancy onwards through their maternity services or GP surgery. Older adults aged 75-79 are also eligible for the jab, and NHS England will start inviting people to come forward in the next few weeks. Symptoms of an RSV infection NHS RSV is a common cause of coughs and colds, but some people have a high risk of getting seriously ill from the virus, including babies and adults over the age of 75. In babies, RSV is a common cause of a type of chest infection called bronchiolitis. Last week, the UK Health Security Agency published data showing the efficacy of the vaccine. It said that the jab for pregnant women can prevent 72 per cent of hospital admissions for their babies. And the vaccine is 82 per cent effective at preventing hospital admissions for RSV among older adults, UKHSA said.
Telegraph
24 minutes ago
- Telegraph
Antimicrobial resistance and the fight to prevent a real-life The Last of Us
In the popular zombie-apocalypse TV show The Last of Us, humans become infected with parasitic fungi, causing a blooming fungal amour to sprout from their skulls. It's gripping TV but in the real-world, deaths from fungal infections have doubled in the last decade and drug-resistant fungi are showing an alarming upward trajectory, making this fictional threat feel uncomfortably close to reality. Antimicrobial resistance (AMR), when fungi, bacteria, viruses and parasites evolve to resist the antimicrobial medicines designed to kill them, is quickly accelerating, fuelling a 'silent pandemic'. Since 1990, at least one million people have died from AMR every year. In the next 25 years, it could cause the deaths of almost 40 million people. Low- and middle-income countries like my own, Nigeria, face a dual challenge. First, a lack of access to antimicrobials leads to more deaths from AMR and actually makes the resistance problem worse. And overuse of antimicrobials in other parts of the world – particularly in healthcare and agriculture – is also fuelling resistance. The result is not just a health crisis but a development emergency. A recent study found that AMR economically hits low- and middle-income countries the hardest. Today, it costs approximately $66 billion and this is set to rise to $159 billion if action is not taken to effectively curb it. In the midst of this worsening crisis, the UK Government recently announced that it is shutting the Fleming Fund – named after the discoverer of penicillin and a key player in the fight against AMR. While bad for UK science and the broader global effort to tackle AMR, it now falls on others to take up the baton to tackle one of the world's most existential threats. The good news is that new leadership is emerging in the countries hit the hardest. This month, the Government of Nigeria announced it will host the fifth Global High-Level Ministerial Conference on AMR in 2026 – the first time the event will be held in Africa. While promising developments, such as the antibiotic zosurabalpin, currently undergoing human trials, or the use of artificial intelligence in drug discovery, give reason for cautious optimism, there is much more to be done to ensure that life-saving treatments are available to the people that need them. First, we must prioritise access to quality diagnostic tools, our first line of defence against AMR. Diagnostics ensure that antimicrobials are used appropriately, increasing patients' chances of recovery while slowing resistance. They also protect new discoveries by preventing unnecessary use. Diagnostics are not just critical for individual patients, they are vital for tracking resistance patterns across animal, and environmental health; sectors which are deeply interlinked in our fight against AMR. Today most of the world is fighting AMR without access to diagnostics. Without them, we're not just under-equipped – we're fighting blind. Second, we must expand access to antimicrobials, create the market conditions needed for further drug development, and ensure that every country implements and enforces a national action plan for AMR. Research in the Lancet across eight low- and middle-income countries found less than seven percent of people with drug-resistant bacterial infections could access the antibiotics they needed. Without these medicines, both patients and the wider community are at risk, as pathogens spread and evolve. Third, we must dramatically increase investment in innovation and strengthen the fragile antimicrobial pipeline. New antimicrobials are urgently needed to meet growing global demand and unmet needs. At the fourth Global High-Level Ministerial Conference on AMR in Jeddah, Saudi Arabia, leaders acknowledged the weak pipeline for new antibiotics and the market failures holding back development. The economic model is broken. Antibiotic research is costly, slow, and high-risk: for new classes of antibiotics, only one in 30 candidates will reach patients, and these are often reserved as a last resort. Government and industry must act urgently and ambitiously to reform the market to mobilise innovation. We need new economic models that reward long-term public health benefits, not just short-term profits. Finally, diagnostic and antimicrobial access and innovations must be backed by strong national action plans. At the second high level meeting on AMR at the 79th United Nations General Assembly, global leaders committed to developing or implementing national AMR action plans. At that time, while 178 countries had developed multi-sectoral national action plans, only 68 percent were implementing these plans. Last year, Nigeria launched its second national action plan on AMR, building on efforts to curb overuse and misuse of antimicrobials across human and animal health. But as we have learnt from Covid-19, pathogens do not know borders. Containing AMR demands global, coordinated action and accountability. We're not in the apocalyptic world of The Last of Us just yet but AMR has long been claiming lives, and is a blight on our health systems and economies. The decisive action we take in the next year will be key to preventing the unravelling of modern medicine.
Telegraph
24 minutes ago
- Telegraph
The UK no longer a ‘reliable partner' in fight against AMR, says City's superbug tsar
The UK is no longer a 'reliable partner' in the global fight against antimicrobial resistance, according to the architect of the government's superbugs strategy. In an interview with The Telegraph, Lord Jim O'Neill said he was 'disillusioned' over the government's decision to shelve The Fleming Fund, a £265 million project aimed at tackling antimicrobial resistance (AMR) in 25 African and Asian countries. 'It sends a message that the UK can't be really regarded as reliable on these big picture, hugely important global health challenges,' Lord O'Neill told The Telegraph. Lord O'Neil, an economist and former chairman of Goldman Sachs, led the 2014 Review on Antimicrobial Resistance on behalf of the British Government, warning there could be 10 million people around the world dying from AMR-related illnesses by 2050 without action. Since the report was published more than a decade ago there has been cross-party support for prioritising the fight against superbugs but last month Labour announced it was closing the Fleming Fund, the UK flagship project in the area. 'It sends this really bad symbolic message around the world ... I'm still a bit stumped as to the lack of awareness of what the consequences are,' Lord O'Neill told the Telegraph. The fund was launched in 2015 following the publication of Lord O'Neil's Review and with the backing of the then Chief Medical Officer Dame Sally Davies. Britain has since become a world leader in the science behind AMR, the Fleming Fund marking a large part of the UK's contributions to the field. AMR is fuelled by the misuse and overuse of antibiotics and other antimicrobials in humans and agriculture and is described by The World Health Organization (WHO) as 'one of the top global public health and development threats.' Already, at least 32,000 people in the UK die of a resistant infection every year, prompting experts to call it a 'silent pandemic'. In February, a review from the National Audit Office (NAO) found the government 'remains a long way' from achieving its aim of containing and controlling AMR. Of five domestic targets set in 2019, just one – to reduce antibiotic use in livestock – has been met. Drug-resistant infections in Britain have increased by 13 per cent since 2018, despite a target to reduce them by 10 per cent, the NAO said. The decision to close the Fleming Fund was made quietly in February by the Labour government and revealed by the Telegraph in July. Fleming Fund money – used to run laboratories, train medical staff, test for resistant infections in hospitals, and share genetic information about mutant bacteria and viruses to global databases – will now run out in March 2026, despite assurances from the government it would be stretch at least another two years, a source with close knowledge of the project told The Telegraph. The source added that the Fleming Fund would have been able to continue functioning with half or even a quarter of its initial financial allocation by the Department of Health and Social Care (DHSC), but simply 'cannot operate with £0.' At a meeting on AMR at the UN General Assembly in New York only last year, Foreign Secretary David Lammy used the Fleming Fund to burnish the country's reputation abroad. He said: 'The UK is working with partners around the world, including through our existing Fleming Fund' in order to 'modernise our approach to development, rooted in a spirit of genuine partnership.' During a parliamentary evidence session in July, Ashley Dalton, Under-Secretary of State for Public Health and Prevention in the Department of Health and Social Care, said despite the decision to axe the fund's funding, the government will continue with its 'partnerships' forged under the Fleming Fund, although did not clarify what this meant. But Ben Simms, CEO of Global Health Partnerships, an organisation which trains and educates health workers in Africa and Asia and whose work is partly funded by the Fleming Fund, told The Telegraph that it was not clear if funding would continue. 'We can see that there is an aspiration to continue [the fund], but it just doesn't look credible at the moment, because there are no financial figures accompanying the aspiration to maintain partnerships, or any financial commitment to maintain a significant contribution on AMR,' Mr Simmons said. Experts have long emphasised that antibiotic resistant infections do not respect borders, and mitigating their spread around the world is vital to safeguard Britain's own health security. Lord O'Neil's 2014 Review concluded that in addition to millions of deaths, there would be massive economic consequences unless AMR was successfully dealt with. 'We projected that the lost economic potential due to AMR between 2015 and 2050 could be a staggering $100 trillion,' he said at the time.
